Try GOLD - Free

High Growth Health Insurance Market Still Remains Underpenetrated

Bio Spectrum

|

February 2018 ,Vol 16 Issue 05

India’s healthcare industry is one of the fastest growing sectors and in the coming 10 years it is expected to reach $275 billion. Indian healthcare sector is much diversified and is full of opportunities in every segment which includes providers, payers and medical technology. With the increase in the competition, businesses are looking to explore for the latest dynamics and trends which will have positive impact on their business.

- Narayan Kulkarni

High Growth Health Insurance Market Still Remains Underpenetrated

Healthcare has become one of India’s largest sectors - both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services and increasing expenditure by public as well private players.

Indian healthcare delivery system is categorised into two major components - public and private. The Government, i.e. public healthcare system comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of primary healthcare centres (PHCs) in rural areas. The private sector provides majority of secondary, tertiary and quaternary care institutions with a major concentration in metros, tier I and tier II cities.

The healthcare sector in India is largely underpenetrated with government expenditure constituting approximately 1.4 per cent of India’s GDP. Private sector expenditure constitutes 70 per cent of the total healthcare expenditure out of which 62 per cent is out of pocket while only 8 per cent is covered through pre-financed instruments, as per World Bank Data (2014). Moreover, less than 30 per cent of India’s population has healthcare cover indicating considerable potential for the health insurance industry.

The health insurance industry, as of today, caters largely to institutional treatment, leading to considerable opportunities in targeting outpatient treatment in areas such as consultation fees, diagnostics and medicine expenses. The outpatient treatment, with medical inflation at ~15 per cent has created a strong need of developing a health savings account product combined with a robust health insurance plan in order to bring in spend efficiencies and protection for the Indian population.

MORE STORIES FROM Bio Spectrum

Bio Spectrum

Bio Spectrum

IASST synthesises new compound to combat aggressive breast cancer

A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.

time to read

1 min

October 2025

Bio Spectrum

DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

WHO unveils updated guideline on HIV service delivery

WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.

time to read

1 min

October 2025

Bio Spectrum

Scientists in Kolkata explore therapeutic potential of accessory proteins

A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

US FDA advances rare disease drug development

The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

time to read

1 min

October 2025

Bio Spectrum

WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

time to read

1 min

October 2025

Bio Spectrum

Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification

Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.

time to read

1 min

October 2025

Bio Spectrum

Aodh Lifesciences gets support from TDB to redefine pneumonia treatment

The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

Antara Senior Care names Mukesh Ghuraiya as Chief Marketing Officer

Antara Senior Care, a fully integrated senior care ecosystem, has appointed Mukesh Ghuraiya as the Executive Vice-President and Chief Marketing Officer (CMO).

time to read

1 min

October 2025

Bio Spectrum

Poly Medicure acquires PendraCare Group for Rs 188.5 Cr

Poly Medicure, a Delhi-based medical device company, has announced signing of definitive agreements to acquire 90 per cent stake in PendraCare Group consisting of PendraCare Holdings and Welling Medical from Welling Holdings B.V. at an Enterprise value of Rs 188.5 crore (Euro 18.3 million).

time to read

1 min

October 2025

Translate

Share

-
+

Change font size